MATERIALS AND METHODS: TRAMP-C1 cells were first characterized for the expression of SSTR1-5 and then were inoculated onto the femur of C57Bl mice. Investigation protocols employed TRAMP-C1 cell proliferation and invasion assays, analysis of radiographic images of the bone lesions and overall survival of the diseased animals.
RESULTS: The triple combination treatment scheme showed significant anticancer effects, in both proliferation and invasion assays, compared to any single agent treatment scheme. DOC treatment following the neoadjuvant administration of DEX plus OCT regimen improved significantly the anticancer effects both on the grading of the bone lesions and on the overall survival of the diseased animals.
CONCLUSION: Our data suggest that the neoadjuvant administration of DEX plus OCT regimen can improve the anticancer effects of DOC on the TRAMP-C1 model.
Written by:
Dalezis P, Geromichalos GD, Trafalis DT, Pissimissis N, Panagiotopoulou D, Galaktidou G, Papageorgiou E, Papageorgiou A, Daifoti Z, Lymperi M, Koutsilieris M. Are you the author?
Department of Experimental Physiology, Medical School, National & Kapodistrian University of Athens, 75 Micras Asias, Goudi-Athens, 115 27, Greece.
Reference: In Vivo. 2012 Jan-Feb;26(1):75-86.
PubMed Abstract
PMID: 22210719
UroToday.com Investigational Urology Section
